therapeuticЮжно-Российский журнал терапевтической практикиSouth Russian Journal of Therapeutic Practice2712-81563033-8344РостГМУ10.21886/2712-8156-2025-6-4-7-15therapeutic-681Research ArticleОБЗОРЫREVIEWSВозможности оптимизации терапии хронической сердечной недостаточности с сохраненной фракцией выброса с помощью применения агонистов рецепторов глюкагоноподобного пептида-1Possibilities of optimizing therapy of heart failure with preserved ejection fraction using glucagon-like peptide-1 receptor agonistshttps://orcid.org/0000-0002-8070-2234КужелеваЕ. А.KuzhelevaE. A.

Кужелева Елена Андреевна, к.м.н., старший научный сотрудник отделения патологии миокарда

Томск

Elena A. Kuzheleva, PhD, Senior Researcher, Department of Myocardial Pathology

Tomsk

kea@cardio-tomsk.ruhttps://orcid.org/0000-0002-9488-6900ГарганееваА. А.GarganeevaA. A.

Гарганеева Алла Анатольевна, д.м.н., профессор, заведующая отделением патологии миокарда

Томск

Alla A. Garganeeva, Dr. Sci (Med.), Professor, Head of the Department of Myocardial Pathology

Tomsk

aag@cardio-tomsk.ruhttps://orcid.org/0009-0009-4372-4782СыромятниковаЕ. Е.SyromyatnikovaE. E.

Сыромятникова Екатерина Егоровна, ординатор отделения патологии миокарда, лаборант-исследователь

Томск

Ekaterina E. Syromyatnikova, Resident, Departmeent of Myocardial Pathology

Tomsk

katy00.syrr@gmail.comhttps://orcid.org/0000-0002-7661-5808ТукишО. В.TukishO. V.

Тукиш Ольга Викторовна, к.м.н., научный сотрудник, отделение патологии  миокарда

Томск

Olga V. Tukish, PhD, Researcher, Departmeent of Myocardial Pathology

Tomsk

olgatukish@yandex.ruНаучно-исследовательский институт кардиологии, Томский национальный исследовательский медицинский центр Российской академии наукРоссияCardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of SciencesRussian Federation20252312202564715Copyright © Кужелева Е.А., Гарганеева А.А., Сыромятникова Е.Е., Тукиш О.В., 20252025Кужелева Е.А., Гарганеева А.А., Сыромятникова Е.Е., Тукиш О.В.Kuzheleva E.A., Garganeeva A.A., Syromyatnikova E.E., Tukish O.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.therapeutic-j.ru/jour/article/view/681

В статье представлен систематический обзор литературы, посвящённый анализу эффективности и безопасности применения агонистов рецепторов глюкагоноподобного пептида-1 (арГПП-1) при хронической сердечной недостаточности (СН) с сохранённой фракцией выброса левого желудочка (ХСНсФВ). Вопрос исследования касался возможностей совместного приёма препаратов из групп ингибиторов натрий-глюкозного котранспортера 2 типа (иНГЛТ2) и арГПП-1. Поиск литературы осуществлялся в системе PubMed. В окончательный анализ вошли 11 исследований, соответствующих изучаемой теме. Согласно анализу, арГПП-1 являются эффективным средством для терапии пациентов с ХСНсФВ, приводя к уменьшению симптомов СН и улучшению качества жизни таких больных. Вопросы одновременного назначения арГПП-1 и иНГЛТ2 достаточно подробно изучены у пациентов с сахарным диабетом 2 типа: продемонстрированы эффективность и безопасность такой комбинации. При отсутствии СД у пациентов с ХСНсФВ оптимизация лечения с использованием класса арГПП-1 требует проведения дополнительных специально спланированных исследований.

The article presents a systematic review of the literature devoted to the analysis of the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RA) in chronic heart failure with preserved ejection fraction (HFpEF). The research question concerned the possibilities of co-administration of drugs from the groups of sodium-glucose cotransporter-2 inhibitors (iSGLT-2) and GLP-1 RA. The literature was searched in the PubMed system. The final analysis included 11 studies relevant to the topic under study. According to the analysis, GLP-1 RA is an effective treatment for patients with CHF, leading to a reduction in HF symptoms and an improvement in the quality of life of such patients. The issues of simultaneous administration of GLP-1 RA and iSGLT-2 have been studied in sufficient detail in patients with type 2 diabetes mellitus: the effectiveness and safety of such a combination have been demonstrated. In the absence of diabetes in patients with HF, optimization of treatment using the GLP-1 RA class requires additional specially planned studies. The article presents a systematic review of the literature devoted to the analysis of the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RA) in chronic heart failure with preserved ejection fraction (HFpEF). The research question concerned the possibilities of co-administration of drugs from the groups of sodium-glucose cotransporter-2 inhibitors (iSGLT-2) and GLP-1 RA. The literature was searched in the PubMed system. The final analysis included 11 studies relevant to the topic under study. According to the analysis, GLP-1 RA is an effective treatment for patients with CHF, leading to a reduction in HF symptoms and an improvement in the quality of life of such patients. The issues of simultaneous administration of GLP-1 RA and iSGLT-2 have been studied in sufficient detail in patients with type 2 diabetes mellitus: the effectiveness and safety of such a combination have been demonstrated. In the absence of diabetes in patients with HF, optimization of treatment using the GLP-1 RA class requires additional specially planned studies.

Хроническая сердечная недостаточностьагонисты рецепторов глюкагоноподобного пептида-1арГПП-1ХСНсФВиНГЛТ2Chronic heart failureglucagon-like peptide-1 receptor agonistsHFpEFiSGLT-2ReferencesGBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789-1858. Erratum in: Lancet. 2019;393(10190):e44. doi: 10.1016/S0140-6736(18)32279-7. Epub 2018 Nov 8.GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789-1858. Erratum in: Lancet. 2019;393(10190):e44. doi: 10.1016/S0140-6736(18)32279-7. Epub 2018 Nov 8.Галявич А.С., Терещенко С.Н., Ускач Т.М., Агеев Ф.Т., Аронов Д.М., Арутюнов Г.П., и др. Хроническая сердечная недостаточность. Клинические рекомендации 2024. Российский кардиологический журнал. 2024;29(11):6162. doi: 10.15829/1560-4071-2024-6162Galyavich A.S., Tereshchenko S.N., Uskach T.M., Ageev F.T., Aronov D.M., Arutyunov G.P., et al. 2024 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2024;29(11):6162. (In Russ.) doi: 10.15829/1560-4071-2024-6162Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032. Erratum in: Circulation. 2022;145(18):e1033. Erratum in: Circulation. 2022;146(13):e185. Erratum in: Circulation. 2023;147(14):e674. doi: 10.1161/CIR.0000000000001063.Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032. Erratum in: Circulation. 2022;145(18):e1033. Erratum in: Circulation. 2022;146(13):e185. Erratum in: Circulation. 2023;147(14):e674. doi: 10.1161/CIR.0000000000001063.McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726. Erratum in: Eur Heart J. 2021;42(48):4901. doi: 10.1093/eurheartj/ehab368.McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726. Erratum in: Eur Heart J. 2021;42(48):4901. doi: 10.1093/eurheartj/ehab368.Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022;387(12):1089-1098. doi: 10.1056/NEJMoa2206286Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022;387(12):1089-1098. doi: 10.1056/NEJMoa2206286Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451-1461. doi: 10.1056/NEJMoa2107038Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451-1461. doi: 10.1056/NEJMoa2107038McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627-3639. Erratum in: Eur Heart J. 2024;45(1):53. doi: 10.1093/eurheartj/ehad195.McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627-3639. Erratum in: Eur Heart J. 2024;45(1):53. doi: 10.1093/eurheartj/ehad195.Черкашин Д.В., Салухов В.В., Халимов Ю.Ш. Сердечно-сосудистые эффекты семаглутида и тирзепатида и их потенциал в кардиопротекции. Медицинский Совет. 2025;19(13):157-172. https://doi.org/10.21518/ms2025-323Cherkashin D.V., Salukhov V.V., Khalimov Y.S. Cardiovascular effects of semaglutide and tirzepatide and their potential for cardioprevention. Meditsinskiy sovet = Medical Council. 2025;19(13):157-172. (In Russ.) https://doi.org/10.21518/ms2025-323Aryee EK, Ozkan B, Ndumele CE. Heart Failure and Obesity: The Latest Pandemic. Prog Cardiovasc Dis. 2023;78:43-48. doi: 10.1016/j.pcad.2023.05.003Aryee EK, Ozkan B, Ndumele CE. Heart Failure and Obesity: The Latest Pandemic. Prog Cardiovasc Dis. 2023;78:43-48. doi: 10.1016/j.pcad.2023.05.003Vest AR, Schauer PR, Rodgers JE, Sanderson E, LaChute CL, Seltz J, et al. Obesity and Weight Loss Strategies for Patients With Heart Failure. JACC Heart Fail. 2024;12(9):1509-1527. doi: 10.1016/j.jchf.2024.06.006Vest AR, Schauer PR, Rodgers JE, Sanderson E, LaChute CL, Seltz J, et al. Obesity and Weight Loss Strategies for Patients With Heart Failure. JACC Heart Fail. 2024;12(9):1509-1527. doi: 10.1016/j.jchf.2024.06.006Shahid I, Khan MS, Butler J, Fonarow GC, Greene SJ. Initiation and sequencing of guideline-directed medical therapy for heart failure across the ejection fraction spectrum. Heart Fail Rev. 2025;30(3):515-523. doi: 10.1007/s10741-025-10481-7Shahid I, Khan MS, Butler J, Fonarow GC, Greene SJ. Initiation and sequencing of guideline-directed medical therapy for heart failure across the ejection fraction spectrum. Heart Fail Rev. 2025;30(3):515-523. doi: 10.1007/s10741-025-10481-7Inciardi RM, Riccardi M, Savarese G, Metra M, Vaduganathan M, Solomon SD. Tailoring medical therapy for heart failure with preserved ejection fraction. Eur J Heart Fail. 2025;27(2):190-193. doi: 10.1002/ejhf.3558Inciardi RM, Riccardi M, Savarese G, Metra M, Vaduganathan M, Solomon SD. Tailoring medical therapy for heart failure with preserved ejection fraction. Eur J Heart Fail. 2025;27(2):190-193. doi: 10.1002/ejhf.3558Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-322. doi: 10.1056/NEJMoa1603827Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-322. doi: 10.1056/NEJMoa1603827Lopez J, Makuvire T, Davis JD, Carbone S. The Short and Sweet on Sodium-Glucose Cotransporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure. US Cardiol. 2025;19:e12. doi: 10.15420/usc.2024.44Lopez J, Makuvire T, Davis JD, Carbone S. The Short and Sweet on Sodium-Glucose Cotransporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure. US Cardiol. 2025;19:e12. doi: 10.15420/usc.2024.44Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844. doi: 10.1056/NEJMoa1607141Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844. doi: 10.1056/NEJMoa1607141Hernandez AF, Green JB, Janmohamed S, D'Agostino RB Sr, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519-1529. doi: 10.1016/S0140-6736(18)32261-XHernandez AF, Green JB, Janmohamed S, D'Agostino RB Sr, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519-1529. doi: 10.1016/S0140-6736(18)32261-XGerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, et al. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. N Engl J Med. 2021;385(10):896-907. doi: 10.1056/NEJMoa2108269Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, et al. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. N Engl J Med. 2021;385(10):896-907. doi: 10.1056/NEJMoa2108269Попов С.В., Бощенко А.А., Маслов Л.Н., Журавлева О.А., Мухомедзянов А.В., Слидневская А.С., и др. Пептиды – кардиопротекторные препараты будущего. Глюкагоноподобный пептид-1. Сибирский журнал клинической и экспериментальной медицины. 2025;40(3):11-18. doi: 10.1016/j.cmet.2016.06.009Popov S.V., Boshchenko A.A., Maslov L.N., Zhuravleva O.A., Mukhomedzyanov A.V., Slidnevskaya A.S., et al. Peptides are cardioprotective drugs of the future. Glucagon-like peptide-1. Siberian Journal of Clinical and Experimental Medicine. 2025;40(3):11-18. (In Russ.) doi: 10.1016/j.cmet.2016.06.009Drucker DJ. The Cardiovascular Biology of Glucagon-like Peptide-1. Cell Metab. 2016;24(1):15-30. doi: 10.1016/j.cmet.2016.06.009Drucker DJ. The Cardiovascular Biology of Glucagon-like Peptide-1. Cell Metab. 2016;24(1):15-30. doi: 10.1016/j.cmet.2016.06.009Smits MM, Van Raalte DH. Corrigendum: Safety of Semaglutide. Front Endocrinol (Lausanne). 2021;12:786732. Erratum for: Front Endocrinol (Lausanne). 2021;12:645563. doi: 10.3389/fendo.2021.786732.Smits MM, Van Raalte DH. Corrigendum: Safety of Semaglutide. Front Endocrinol (Lausanne). 2021;12:786732. Erratum for: Front Endocrinol (Lausanne). 2021;12:645563. doi: 10.3389/fendo.2021.786732.Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. doi: 10.1056/NEJMoa2307563Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. doi: 10.1056/NEJMoa2307563Deanfield J, Verma S, Scirica BM, Kahn SE, Emerson SS, Ryan D, et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet. 2024;404(10454):773-786. doi: 10.1016/S0140-6736(24)01498-3Deanfield J, Verma S, Scirica BM, Kahn SE, Emerson SS, Ryan D, et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet. 2024;404(10454):773-786. doi: 10.1016/S0140-6736(24)01498-3Butler J, Abildstrøm SZ, Borlaug BA, Davies MJ, Kitzman DW, Petrie MC, et al. Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction. J Am Coll Cardiol. 2023;82(22):2087-2096. doi: 10.1016/j.jacc.2023.09.811Butler J, Abildstrøm SZ, Borlaug BA, Davies MJ, Kitzman DW, Petrie MC, et al. Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction. J Am Coll Cardiol. 2023;82(22):2087-2096. doi: 10.1016/j.jacc.2023.09.811Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Christensen L, Davies M, et al. Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype. JACC Heart Fail. 2023;11(8 Pt 1):1000-1010. doi: 10.1016/j.jchf.2023.05.010Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Christensen L, Davies M, et al. Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype. JACC Heart Fail. 2023;11(8 Pt 1):1000-1010. doi: 10.1016/j.jchf.2023.05.010Harrington J. STEP HFpEF DM: a sweet sequel. Heart Fail Rev. 2024;29(5):913-915. doi: 10.1007/s10741-024-10408-8Harrington J. STEP HFpEF DM: a sweet sequel. Heart Fail Rev. 2024;29(5):913-915. doi: 10.1007/s10741-024-10408-8Butler J, Shah SJ, Petrie MC, Borlaug BA, Abildstrøm SZ, Davies MJ, et al. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. Lancet. 2024;403(10437):1635-1648. doi: 10.1016/S0140-6736(24)00469-0Butler J, Shah SJ, Petrie MC, Borlaug BA, Abildstrøm SZ, Davies MJ, et al. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. Lancet. 2024;403(10437):1635-1648. doi: 10.1016/S0140-6736(24)00469-0Kosiborod MN, Deanfield J, Pratley R, Borlaug BA, Butler J, Davies MJ, et al. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet. 2024;404(10456):949-961. doi: 10.1016/S0140-6736(24)01643-XKosiborod MN, Deanfield J, Pratley R, Borlaug BA, Butler J, Davies MJ, et al. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet. 2024;404(10456):949-961. doi: 10.1016/S0140-6736(24)01643-XMann JFE, Rossing P, Bakris G, Belmar N, Bosch-Traberg H, Busch R, et al. Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. Nat Med. 2024;30(10):2849-2856. doi: 10.1038/s41591-024-03133-0Mann JFE, Rossing P, Bakris G, Belmar N, Bosch-Traberg H, Busch R, et al. Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. Nat Med. 2024;30(10):2849-2856. doi: 10.1038/s41591-024-03133-0Marx N, Deanfield JE, Mann JFE, Arechavaleta R, Bain SC, Bajaj HS, et al. Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial. Circulation. 2025;151(23):1639-1650. doi: 10.1161/CIRCULATIONAHA.125.074545Marx N, Deanfield JE, Mann JFE, Arechavaleta R, Bain SC, Bajaj HS, et al. Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial. Circulation. 2025;151(23):1639-1650. doi: 10.1161/CIRCULATIONAHA.125.074545Zinman B, Bhosekar V, Busch R, Holst I, Ludvik B, Thielke D, et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7(5):356-367. Erratum in: Lancet Diabetes Endocrinol. 2019;7(5):e5. Erratum in: Lancet Diabetes Endocrinol. 2019;7(8):e20. Erratum in: Lancet Diabetes Endocrinol. 2019;7(11):e22. doi: 10.1016/S2213-8587(19)30066-XZinman B, Bhosekar V, Busch R, Holst I, Ludvik B, Thielke D, et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7(5):356-367. Erratum in: Lancet Diabetes Endocrinol. 2019;7(5):e5. Erratum in: Lancet Diabetes Endocrinol. 2019;7(8):e20. Erratum in: Lancet Diabetes Endocrinol. 2019;7(11):e22. doi: 10.1016/S2213-8587(19)30066-XTerauchi Y, Fujiwara H, Kurihara Y, Suganami H, Tamura M, Senda M, et al. Long-term safety and efficacy of the sodium-glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week open-label, multicenter, post-marketing clinical study. J Diabetes Investig. 2019;10(6):1518-1526. doi: 10.1111/jdi.13066Terauchi Y, Fujiwara H, Kurihara Y, Suganami H, Tamura M, Senda M, et al. Long-term safety and efficacy of the sodium-glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week open-label, multicenter, post-marketing clinical study. J Diabetes Investig. 2019;10(6):1518-1526. doi: 10.1111/jdi.13066Lam CSP, Ramasundarahettige C, Branch KRH, Sattar N, Rosenstock J, Pratley R, et al. Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial. Circulation. 2022;145(8):565-574. Erratum in: Circulation. 2023;147(23):e720. doi: 10.1161/CIRCULATIONAHA.121.057934.Lam CSP, Ramasundarahettige C, Branch KRH, Sattar N, Rosenstock J, Pratley R, et al. Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial. Circulation. 2022;145(8):565-574. Erratum in: Circulation. 2023;147(23):e720. doi: 10.1161/CIRCULATIONAHA.121.057934.Vernstrøm L, Gullaksen S, Sørensen SS, Funck KL, Laugesen E, Poulsen PL. Separate and combined effects of empagliflozin and semaglutide on vascular function: A 32-week randomized trial. Diabetes Obes Metab. 2024;26(5):1624-1635. doi: 10.1111/dom.15464Vernstrøm L, Gullaksen S, Sørensen SS, Funck KL, Laugesen E, Poulsen PL. Separate and combined effects of empagliflozin and semaglutide on vascular function: A 32-week randomized trial. Diabetes Obes Metab. 2024;26(5):1624-1635. doi: 10.1111/dom.15464Katogiannis K, Thymis J, Kousathana F, Pavlidis G, Korakas E, Kountouri A, et al. Effects of Liraglutide, Empagliflozin and Their Combination on Left Atrial Strain and Arterial Function. Medicina (Kaunas). 2024;60(3):395. doi: 10.3390/medicina60030395Katogiannis K, Thymis J, Kousathana F, Pavlidis G, Korakas E, Kountouri A, et al. Effects of Liraglutide, Empagliflozin and Their Combination on Left Atrial Strain and Arterial Function. Medicina (Kaunas). 2024;60(3):395. doi: 10.3390/medicina60030395Arnott C, Neuen BL, Heerspink HJL, Figtree GA, Kosiborod M, Lam CS, et al. The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program. Int J Cardiol. 2020;318:126-129. doi: 10.1016/j.ijcard.2020.06.011Arnott C, Neuen BL, Heerspink HJL, Figtree GA, Kosiborod M, Lam CS, et al. The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program. Int J Cardiol. 2020;318:126-129. doi: 10.1016/j.ijcard.2020.06.011Agarwal R, Green JB, Heerspink HJL, Mann JFE, McGill JB, Mottl AK, et al. Impact of Baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and Chronic Kidney Disease (CONFIDENCE Trial). Diabetes Care. 2025;48(11):1904-1913. doi: 10.2337/dc25-1673Agarwal R, Green JB, Heerspink HJL, Mann JFE, McGill JB, Mottl AK, et al. Impact of Baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and Chronic Kidney Disease (CONFIDENCE Trial). Diabetes Care. 2025;48(11):1904-1913. doi: 10.2337/dc25-1673Sivalingam S, Wasehuus VS, Rotbain Curovic V, Blond MB, Hansen TW, Persson F, et al. Albuminuria-lowering effect of adding semaglutide on top of empagliflozin in individuals with type 2 diabetes: A randomized and placebo-controlled study. Diabetes Obes Metab. 2024;26(1):54-64. doi: 10.1111/dom.15287Sivalingam S, Wasehuus VS, Rotbain Curovic V, Blond MB, Hansen TW, Persson F, et al. Albuminuria-lowering effect of adding semaglutide on top of empagliflozin in individuals with type 2 diabetes: A randomized and placebo-controlled study. Diabetes Obes Metab. 2024;26(1):54-64. doi: 10.1111/dom.15287Chen SY, Wu JY, Liao KM, Lin YM. Prognostic benefit of glucagon-like peptide-1 receptor agonists addition to sodium-glucose cotransporter 2 inhibitors in patients with atherosclerotic cardiovascular disease and heart failure: a cohort study. Eur Heart J Cardiovasc Pharmacother. 2025;11(4):324-333. doi: 10.1093/ehjcvp/pvaf014.Chen SY, Wu JY, Liao KM, Lin YM. Prognostic benefit of glucagon-like peptide-1 receptor agonists addition to sodium-glucose cotransporter 2 inhibitors in patients with atherosclerotic cardiovascular disease and heart failure: a cohort study. Eur Heart J Cardiovasc Pharmacother. 2025;11(4):324-333. doi: 10.1093/ehjcvp/pvaf014.Ferreira JP, Sharma A, Butler J, Packer M, Zannad F, Vasques-Nóvoa F, et al. Glucagon-Like Peptide-1 Receptor Agonists Across the Spectrum of Heart Failure. J Clin Endocrinol Metab. 2023;109(1):4-9. doi: 10.1210/clinem/dgad398Ferreira JP, Sharma A, Butler J, Packer M, Zannad F, Vasques-Nóvoa F, et al. Glucagon-Like Peptide-1 Receptor Agonists Across the Spectrum of Heart Failure. J Clin Endocrinol Metab. 2023;109(1):4-9. doi: 10.1210/clinem/dgad398Apperloo EM, Neuen BL, Fletcher RA, Jongs N, Anker SD, Bhatt DL, et al. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2024;12(8):545-557. doi: 10.1016/S2213-8587(24)00155-4.Apperloo EM, Neuen BL, Fletcher RA, Jongs N, Anker SD, Bhatt DL, et al. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2024;12(8):545-557. doi: 10.1016/S2213-8587(24)00155-4.

The authors declare that there are no conflicts of interest present.